Company description

AXSM, or Axsome Therapeutics, is a biopharmaceutical company that focuses on developing therapies for central nervous system (CNS) disorders. Founded in 2012, the company is based in New York City and has a diverse portfolio of product candidates targeting major CNS conditions such as depression, opioid addiction, Alzheimer's disease, and other rare disorders. It prides itself on its innovative approach to drug development, utilizing cutting-edge science to create novel treatments that address significant unmet medical needs. One of its most promising candidates is AXS-05, a combination therapy for major depressive disorder and smoking cessation, which has shown promising results in clinical trials. Additionally, the company has several other product candidates in various stages of development, and has received significant funding and recognition from the industry. With a strong management team, a broad therapeutic focus, and a dedication to transforming the lives of patients, AXSM is poised for continued success in the ever-growing biopharmaceutical market.